New injection aims to tame dangerous blood fats

NCT ID NCT06797401

Recruiting now Disease control Sponsor: Ribocure Pharmaceuticals AB Source: ClinicalTrials.gov ↗

Summary

This study is testing whether a new injectable drug called RBD5044 can safely lower high levels of triglycerides and other fats in the blood of adults with mixed dyslipidemia. About 120 participants will receive either the drug or a placebo injection and be monitored for nearly a year. The main goal is to see how well the drug reduces triglyceride levels after 16 weeks compared to a dummy treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIAS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Akademiska Sjukhuset Uppsala
RECRUITING

Uppsala, Sweden

Contact
AkardoMedSite
RECRUITING

Stockholm, Sweden

Contact
Lunds Universitetssjukhus
RECRUITING

Lund, Sweden

Contact
Ribocure Clinic/Ribocure Pharmaceuticals AB
RECRUITING

Mölndal, Sweden

Contact

Conditions

Explore the condition pages connected to this study.

DYSLIPIDEMIAS